Article

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy Outcomes

2021-05-03

Abstract excerpt

<title>Abstract</title> <p>The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival (DFS) of resected EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with TKI, raising the necessity for further biomarker assessment. By comprehensive genomic profiling of 171 tumor tissues...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d5379994-cce0-51e8-99d5-1a594187bce8
DOI: 10.21203/rs.3.rs-457070/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy OutcomesDOI 10.21203/rs.3.rs-457070/v1Read

Pooled Analysis of the Prognostic Significance of Epidermal Growth Factor Receptor (EGFR) Mutational Status in Combination with Other Driver Genomic Alterations in Stage I Resected Invasive Lung Adenocarcinoma for Recurrence-Free Survival: A Population-Based Study.Semantic proximity Read

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read

Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read

Retrospective study on the clinicogenomic characteristics of <i>EGFR</i> mutant and wildtype NSCLCSemantic proximity Read

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.Semantic proximity Read

Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.Semantic proximity Read

Genomic Insights into Innate Resistance in Early-Stage EGFR-Mutant Non-Small Cell Lung Cancer: A Comprehensive Analysis of Next-Generation Sequencing Data.Semantic proximity Read

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerSemantic proximity Read

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.Semantic proximity Read

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read

Clinical and Genomic Determinants of Survival in EGFR-Mutant Non-Small Cell Lung Cancer: An Integrated Analysis of UK Biobank and cBioPortal CohortsSemantic proximity Read

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity Read